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Social dysfunction is common in patients with psychotic disorders. Oxytocin is a neuropep-
tide with a central role in social behavior.This study aims to explore the relationship between
oxytocin pathway genes and symptoms related to social dysfunction in patients with psy-
chotic disorders.We performed association analyses between four oxytocin pathway genes
(OXT, OXTR, AVP, and CD38) and four areas of social behavior-related psychopathology as
measured by Positive and Negative Syndrome Scale. For this purpose, we used both a
polygenic risk score (PGRS) and single OXTR candidate single nucleotide polymorphism
previously reported in the literature (rs53576, rs237902, and rs2254298). A total of 734 sub-
jects with DSM-IV psychotic spectrum disorders and 420 healthy controls were included.
Oxytocin pathway PGRSs were calculated based on the independent Psychiatric Genomics
Consortium study sample.There was a significant association between symptom of Emo-
tional Withdrawal and the previously reported OXTR risk allele A in rs53576. No significant
associations between oxytocin pathway gene variants and a diagnosis of psychotic disor-
der were found. Our findings indicate that while oxytocin pathway genes do not appear to
contribute to the susceptibility to psychotic disorders, variations in the OXTR gene might
play a role in the development of impaired social behavior.
Keywords: oxytocin, vasopressin, schizophrenia, psychotic disorders, single nucleotide polymorphisms, polygenic
risk score
INTRODUCTION
Oxytocin and vasopressin are closely related neuropeptide hor-
mones, with similarities in structure, gene locations, pharmaco-
logical properties (Manning et al., 2008), and with roles in relation
to social behavior (Insel and Young, 2001); including social mem-
ory, pair bonding, and parental behavior (Ferguson et al., 2001;
Jin et al., 2007). Administration of intranasal oxytocin in humans
has indicated increased interpersonal trust (Kosfeld et al., 2005),
lower anxiety levels and improved social cognition (Macdonald
and Macdonald, 2010). An increasing number of studies have
investigated the relationship between oxytocin- and vasopressin-
related genes and social behavior, including trust-related clinical
phenotypes. This includes the genes coding for the production of
oxytocin (OXT), vasopressin (AVP), the oxytocin receptor (OXTR)
in addition to CD38, a transmembrane protein important for oxy-
tocin secretion in the central nervous system (Bartz and McInnes,
2007; Jin et al., 2007; Lopatina et al., 2012).
The OXTR polymorphisms rs53576 and rs2254298 are seen as
particularly promising candidates (Meyer-Lindenberg et al., 2011;
Kumsta and Heinrichs, 2013). Multiple studies have indicated the
A allele of rs53576 as a potential risk allele for social impairment.
This allele has been associated with increased risk for autism in
a Chinese Han population (Wu et al., 2005), less maternal sensi-
tivity (Bakermans-Kranenburg and van Ijzendoorn, 2008), lower
dispositional and behavioral empathy (Rodrigues et al., 2009) and
lower sociability, reliance on social approval and learning from
interpersonal feedback (Tost et al., 2010), lower positive affect in
male, healthy subjects (Lucht et al., 2009), more feelings of lone-
liness in healthy females (van Roekel et al., 2013), and lower trust
behavior in healthy subjects (Krueger et al., 2013). Variants in
rs2254298 are found to be associated with risk of autism spec-
trum disorders (ASD), amygdala volume, anxiety, and depression
(Meyer-Lindenberg et al., 2011; Kumsta and Heinrichs, 2013).
However, both a recent large scale study (N~11000) (Chang et al.,
2014) and a recent meta-analysis (N = 48 studies and 17559 par-
ticipants for rs53576 and 34 studies and 13547 participants for
rs2254298) (Bakermans-Kranenburg and van Ijzendoorn, 2014)
did not find any associations to trust-related behavior for these
two single nucleotide polymorphism (SNP) when combining the
original studies.
Psychotic disorders, in particular schizophrenia, are charac-
terized by severe social dysfunction (Green and Phillips, 2004;
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Addington et al., 2006, 2010; Reichenberg, 2010; Schmidt et al.,
2011; Kidd, 2013). The oxytocin–vasopressin system’s effects on
social behaviors, and oxytocin’s potential as a treatment option
in disorders with social dysfunctions (Viero et al., 2010; Pedersen
et al., 2011; Mah et al., 2013), made oxytocin the focus of inter-
est in regard to psychotic disorders (Fischer-Shofty et al., 2013b).
Oxytocin plasma levels have been found to correlate with social
cognitive measures in patients with schizophrenia and healthy
controls (Keri et al., 2009; Walss-Bass et al., 2013; Rubin et al.,
2014) as well as positive symptoms in schizophrenia (Rubin et al.,
2014). Vasopressin plasma levels have been found to be reduced in
both patients and relatives (Rubin et al., 2014) and associated with
positive symptoms and cognitive impairments in subgroups of
psychotic patients (Rubin et al., 2013). Oxytocin’s effect on social
behavior has made it a particular candidate for the treatment of
negative symptoms in schizophrenia (Davis et al., 2014; Millan
et al., 2014).
A few case–control studies to investigate oxytocin gene varia-
tion as a potential risk factor for psychotic disorders have been
undertaken, and some candidate risk SNPs have been suggested
(Souza et al., 2010; Teltsh et al., 2011; Montag et al., 2012). How-
ever, these studies have been small and a recent meta-analysis
was not able to detect any associations between OXTR SNPs
and the risk of schizophrenia (Watanabe et al., 2012). OXTR
SNPs have however been found to be associated with clinical
symptomatology in patients with schizophrenia, including general
psychopathology (rs53576 and rs2254298), negative symptoms as
measured by the Positive and Negative Syndrome Scale (PANSS)
(rs237902), and empathic concern (rs2254298) (Montag et al.,
2012, 2013).
Based on the inconclusive results of the few previous mole-
cular genetic studies in this area, our aims were to investigate
the relationship between variations in oxytocin-related genes and
social behavior-related psychopathology in a large patient sample
with psychotic disorders [i.e., schizophrenia and bipolar disor-
ders (BD)] using two different approaches. The first and most
novel approach was to investigate a measure related to the over-
all effect of oxytocin pathway genes, a polygenic risk score (PGRS)
for OXT, AVP, CD38, and OXTR polymorphisms. Since each single
risk variant in psychotic disorders has a small effect on disease phe-
notypes, this is a method to estimate cumulative genetic risk. We
here assign a PGRS to individual cases in an independent sample
based on summary statistics from one discovery case–control sam-
ple. The PGRS can include a few genome-wide significant SNPs,
millions of SNPs from the entire genome or SNPs with significance
over a certain threshold in a specific pathway. The method can be
used to predict both case–control status and to explore potential
intermediate phenotypes (Purcell et al., 2009; Tesli et al., 2014).
We additionally wanted to replicate findings regarding SNPs
found to be associated either to schizophrenia or social behavior-
related psychopathology (OXTR SNPs rs53576, rs2254298, and
rs237902) in several previous studies. In both cases, we investigated
potential associations with symptom measures chosen a priori
due to their basis in aspects of social behavior: i.e., suspicious-
ness/persecution (p6), hostility (p7), emotional withdrawal (n2),
and passive/apathetic social withdrawal (n4) from the PANSS (Kay
et al., 1987).
MATERIALS AND METHODS
ETHICS STATEMENT
The study was approved by the Regional Committee for Med-
ical Research Ethics and the Norwegian Data Inspectorate and
was conducted according to the principles of the Declaration of
Helsinki. All participants were adequately informed of the back-
ground, purpose, methods, sources of funding, potential benefits,
and discomforts as well as the further storage and use of the data
collected in this study. Potential subjects were informed of their
right to withdraw their consent at any time. Each subject pro-
vided their freely given, written informed consent prior to the
collection of data. Some patients with schizophrenia or BD may
have a reduced ability to give informed consent, but in the current
study only participants with a capacity to consent were included.
This was specifically assessed by the clinical recruitment teams,
which included experienced clinical psychologists or psychiatrists,
according to a procedure approved by the local Regional Com-
mittee for Medical Research Ethics. Potential participants who
declined to participate were not disadvantaged in any way by not
participating in the study, and received same quality and amount
of treatment and care from the hospital as the participants.
SAMPLE CHARACTERISTICS
Participants were included in the Norwegian multicentre The-
matically Organized Psychosis Research (TOP) study recruiting
patients from in- and out-patient clinics in South-Eastern Norway.
All participants in this part of the study were Caucasian and diag-
nosed with a psychotic spectrum disorder according to DSM-IV
using Structured Clinical Interview for DSM-IV Axis 1 Disorders
(SCID-1). None had a history of head injury, neurological disor-
der, autoimmune or infectious disorders or malignancies, or an IQ
below 70. All patients were examined by a physician and fasting
blood samples were drawn in the morning. Of the total sample
of 734 with a schizophrenia PGRS, 731 also had genotyped or
imputation data for the three OXTR SNPs of interest, and 725 had
available symptom scores (Table 1). The sample of 734 patients
covered the following diagnoses: schizophrenia (n= 265, out of
which 262 had data for the SNPs of interest and 263 had symp-
tom scores), schizophreniform disorder (n= 23), schizoaffective
Table 1 | Demographic and clinical background of the study sample
included in PANSS analysis and healthy controls.
Parameters Patients Controls
N Mean±SD N Mean±SD
Age (years) 725 33.4±11.2 411 34.7±9.9
Gender (m/f) 725 361/364 412 208/204
Schizophrenia (N/%) 263/36.3% – –
Education (mean years) 707 13.5±2.9 –
PANSS score p6 724 2.33±1.5 –
PANSS score p7 724 1.22±0.6 –
PANSS score n2 724 2.04±1.2 –
PANSS score n4 724 2.19±1.4 –
PANSS, positive and negative syndrome scale.
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disorder (n= 62), BD I (n= 180), BD II (n= 72), BD not other-
wise specified (n= 18), depressive psychosis (n= 21), and other
psychosis (n= 93). Age- and sex-matched healthy controls were
selected randomly from the same catchment area as the TOP sam-
ple and screened for the presence of severe mental disorders in the
participant and in first-degree relatives. The control sample con-
sisted of 420 subjects with genotyped or imputation data for SNPs
of interest, out of which 417 had PGRSs. None had a history of
head injury or neurological disorders, none were illicit drug users
and finally none had medical problems that in some way could
interfere with brain function.
ASSESSMENTS
For assessment of social dysfunction, we used the PANSS (Kay
et al., 1987). This scale measures psychopathology that is com-
mon in psychotic disorders for the last week: positive, negative,
depressive, disorganized, and excitative symptoms by a 30-item,
7-point rating scale (Langeveld et al., 2013). The scale includes
a thorough definition of the content and behavioral manifesta-
tions of each symptom/item with descriptions of each anchor
point of the scale. The ratings are based on information elicited
through a semi-structured interview and is based on the patients’
thought content as conveyed during the interview information
from informants and clinical observation during the interview.
For the current study, we pre-selected the four items that were
clearly related to trust and social function as defined by their def-
initions; two positive symptoms (p) and two negative symptoms
(n): Suspiciousness/Persecution (p6); e.g., unrealistic or exagger-
ated ideas of persecution, as reflected in guardedness, a distrustful
attitude, suspicious hypervigilance, or frank delusions that others
mean harm, Hostility (p7); e.g., verbal and non-verbal expressions
of anger and resentment, including sarcasm, passive-aggressive
behavior, verbal abuse, and assaultiveness, Emotional Withdrawal
(n2); e.g., lack of interest in, involvement with, and affective com-
mitment to life’s events and Passive/Apathetic Social Withdrawal
(n4); e.g., diminished interest and initiative in social interac-
tions due to passivity, apathy, anergy, or avolition that leads to
reduced interpersonal involvements and neglect of activities of
daily living.
GENE SELECTION AND GENOTYPING
As outlined above, we used two different approaches for the selec-
tion of genetic variants to answer our research questions. The
first was to investigate an overall effect of oxytocin pathway genes
by calculating a PGRS for schizophrenia for OXT, AVP, CD38,
and OXTR polymorphisms using the results from an independent
schizophrenia case–control study (Psychiatric Genomics Consor-
tium (PGC), 2011). The second approach was to select SNPs
previously associated to schizophrenia or to social behavior-related
symptoms. For this purpose, the three OXTR SNPs, rs53576,
rs2254298, and rs237902, were included. The sample was geno-
typed using the Affymetrix Genome-Wide Human SNP Array 6.0
(Affymetrix Inc., Santa Clara, CA, USA). Samples were excluded
through quality control if they had low-yield (call rate below 97%),
if they were duplicates of other samples, if they had a sex deter-
mined by X chromosome marker homozygosity different from
their reported sex or if they were calculated to have other ancestry
than European (Athanasiu et al., 2010). Markers with severe
deviation from Hardy–Weinberg equilibrium, low-yield (<95%)
or with minor allele frequencies below 0.05 were excluded.
IMPUTATION OF SNPs
Following the above mentioned quality control, the candidate
SNPs were imputed with MaCH [43]1 using the European sam-
ples in the Phase I release of the 1000 Genomes Project [SNPs not
present in the 1000 Genomes reference, and SNPs with ambiguous
strand alignments (A/T and G/C SNPs), were removed from the
sample data sets]. Imputation was a three stage process, involving
(I) ChunkChromosome where the data set was broken into 2500
SNP pieces with 500 SNP overlap2, (II) MaCH where each piece
was phased (40 rounds and 400 states)3, and (III) Minimac where
each phased piece was imputed to the 1000 Genomes European
reference panel (20 rounds and 400 states)4. In the third stage, all
imputed SNPs were provided with an estimated r2 score as quality
metric. Exclusions were made of SNPs with an r2 score <0.5 and
with a minor allele frequency <0.01 leaving 9,584,802 SNPs. The
imputed SNPs used in the PGRS were pruned to obtain a set of
independent alleles in linkage equilibrium at r2< 0.25.
POLYGENIC RISK SCORE
A PGRS for the schizophrenia phenotype was computed based
on imputed SNPs following the method developed by Purcell and
co-workers (Purcell et al., 2009) and described in details for the
current sample elsewhere (Tesli et al., 2014). With the aid of PLINK
version 1.075 (40), we performed a meta-analysis including all sub-
studies in the Psychiatric Genomics Consortium (PGC) (2011)
except the current sample (TOP sample) (n= 9146 schizophrenia
cases and 12111 controls), to obtain risk allele effect sizes [ln(OR)]
for SNPs in the oxytocin pathway genes: OXT [OMIM 167050],
OXTR [OMIM 167055], CD38 [OMIM 107270], and AVP [OMIM
192340]. The SNPs within each gene were subsequently pruned by
grouping them in LD (r2< 0.25) sets and selecting from each
set the representative with the highest absolute effect size. This
procedure left us with 32 SNPs: (rs11087565 and rs857240) in
AVP; (rs10805347, rs17476066, rs1803404, rs3733593, rs3756243,
rs3796878, and rs7655635) in CD38; (rs2326055, rs4815560, and
rs6084253) in OXT; and (rs1008642, rs1042778, rs13087941,
rs17049532, rs17049552, rs2072582, rs2268484, rs2268491,
rs2268494, rs2268495, rs2270463, rs2270465, rs2301261, rs237860,
rs237864, rs237888, rs237889, rs237899, rs6443206, and
rs7629329) in OXTR. A cumulative risk score was then computed
for each individual in the TOP sample summing up the effect sizes
of the selected SNPs multiplied by the number of risk alleles car-
ried by that individual. Such a cumulative risk score is assumed to
represent an oxytocin pathway cumulative risk for schizophrenia.
STATISTICAL ANALYSIS
Polygenic risk score vs. psychotic phenotypes
Potential differences in mean schizophrenia oxytocin pathway
PGRS between cases and healthy controls were first investigated
1http://www.sph.umich.edu/csg/abecasis/MACH/download/
1000G-PhaseI-Interim.html
2http://genome.sph.umich.edu/wiki/ChunkChromosome
3http://www.sph.umich.edu/csg/abecasis/MaCH/download/
4http://genome.sph.umich.edu/wiki/Minimac
5http://pngu.mgh.harvard.edu/purcell/plink/
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with t -tests for independent samples (SPSS version 19). These
analyses were performed for the entire psychosis spectrum as well
as in schizophrenia cases only. The PGRSs were normally distrib-
uted according to visual inspection of histograms. Additionally,
we performed linear regression analyses with the four PANSS
scores [suspiciousness/persecution (p6), hostility (p7), emotional
withdrawal (n2), and passive/apathetic social withdrawal (n4)] as
dependent variables and with the PGRS as an independent vari-
able (SPSS version 19) in the total patient sample, correcting for
gender and diagnostic group (schizophrenia spectrum vs. affective
spectrum). Because social dysfunction is particularly pronounced
in schizophrenia, we did a follow-up analysis for the case–control
sample including only patients meeting the diagnostic criteria for
schizophrenia.
Single SNPs vs. psychotic phenotypes
The case–control association analysis between the SNP of inter-
est (rs53576) and a psychotic disorder diagnosis was performed
with an allele model and gender as covariate (PLINK version
1.07), with a follow-up analysis restricted to cases with schizo-
phrenia vs. healthy controls. Statistical power was estimated with
the Genetic Power Calculator6, assuming a disease prevalence of
0.01 for schizophrenia and 0.02 for psychotic disorders, an addi-
tive allelic model and a type I error rate of 0.05. The high risk
allele frequency was 0.67 and the powers were estimated to be
0.51 for psychotic disorders and 0.34 for schizophrenia. We then
undertook linear regression analyses with PANSS p6, p7, n2, n4 as
dependent variables and the SNPs of interest [rs53576, rs2254298
(imputed SNPs), and rs237902 (genotyped SNP)] as independent
6http://pngu.mgh.harvard.edu/~purcell/gpc/
variables (PLINK version 1.07), correcting for gender and diag-
nostic group. The polymorphisms were divided into three groups
(homozygote minor allele, heterozygote, and homozygote major
allele) and analyzed with an additive model.
Additionally, we ran multiple regression analyses for each
PANSS item separately for the three candidate SNPs, to test for
potential specificity of each SNP. These analyses were performed
with the software R. Bonferroni correction was applied to both
single SNP and multiple regression analyses.
RESULTS
POLYGENIC RISK SCORE VS. PSYCHOTIC PHENOTYPES
There was no statistically significant association between the schiz-
ophrenia oxytocin pathway PGRS and either the diagnosis of
psychotic disorders/schizophrenia or to psychopathology related
to social behaviors as measured by the selected PANSS items. All
associations between PGRS scores and clinical symptoms were low
(coefficients ranging from 0.002 to 0.027/p-values ranging from
0.50 to 0.99).
SINGLE SNPs VS. PSYCHOTIC PHENOTYPES
In the study of SNPs of interest, we did not find any associa-
tion between rs53576 and the risk of having a psychotic disorder
per se or to schizophrenia in particular. We found a statistically sig-
nificant association between rs53576 and the level of Emotional
Withdrawal (n2) (nominal p= 0.007; p= 0.084 after Bonferroni
correction taking into consideration the four PANSS items and
the three SNPs). We did not find any associations between single
SNPs and the other symptom scores (Table 2). The multiple regres-
sion analyses indicated a significant association between rs53576
and the level of Emotional Withdrawal (nominal p= 0.00225;
p= 0.009 after Bonferroni correction taking into consideration
the four PANSS items).
Table 2 | Association analysis between PANSS scores and oxytocin receptor polymorphisms.
SNP Nearest
gene
Reference
allelea
N PANSS
item
Beta P (Bonferroni) P multiple regression
(Bonferroni)
rs53576 OXTR G 725 P6 0.123 0.159 (1) 0.561 (1)
724 P7 −0.032 0.387 (1) 0.230 (0.92)
724 N2 −0.203 0.007 (0.084) 0.00225 (0.009)
724 N4 −0.159 0.060 (0.72) 0.209 (0.836)
rs237902 OXTR A 721 P6 0.145 0.055 (0.66) 0.160 (0.640)
721 P7 −0.016 0.574 (1) 0.982 (1)
721 N2 0.018 0.791 (1) 0.238 (0.952)
721 N4 −0.047 0.529 (1) 0.822 (1)
rs2254298 OXTR G 725 P6 0.008 0.941 (1) 0.973 (1)
724 P7 0.055 0.909 (1) 0.739 (1)
724 N2 0.054 0.573 (1) 0.992 (1)
724 N4 0.015 0.890 (1) 0.507 (1)
SNP, single nucleotide polymorphism; OXTR, oxytocin receptor gene; PANSS, positive and negative syndrome scale.
The multiple regression analyses include all three SNPs, sex and diagnosis as predictor variables for each PANSS item.
aAn additive model is used, where the Beta value refers to the increase in the dependent variable for each added reference allele.
Bold font means significant after Bonferroni correction.
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DISCUSSION
The main finding of the current study was a statistically signifi-
cant association between rs53576 in OXTR, frequently found to
be associated with social behavior in previous studies, and the
level of Emotional Withdrawal, a negative symptom frequently
occurring in psychotic disorders. More specifically; we found that
having the risk allele A in rs53576 was associated with higher scores
on Emotional Withdrawal as measured by the PANSS. Emotional
Withdrawal is characterized by the lack of interest in, involvement
with and affective commitment to life’s events and is seen in a wide
range of psychiatric diseases. This finding thus supports previous
ones of a negative association with social behavior for the A allele
for areas covering maternal sensitivity (Bakermans-Kranenburg
and van Ijzendoorn, 2008), empathy (Rodrigues et al., 2009), socia-
bility (Tost et al., 2010), trust behavior in healthy subjects (Krueger
et al., 2013), and seeking of emotional support in times of distress
(Kim et al., 2010). Contrasting studies have however indicated that
schizophrenia patients carrying the G allele had higher general
psychopathology scores measured by PANSS (Montag et al., 2013)
and ADHD children carrying the A allele had better social cogni-
tive ability (Park et al.,2010). These could be in line with a“flip-flop
phenomenon” (Lin et al., 2007) or influenced by different ethnic
sample backgrounds (Propper et al., 2007). Or they could also be
spurious findings due to small samples and low statistical power
(Button et al., 2013) as indicated by the meta-analyses (Psychiatric
Genomics Consortium (PGC), 2011; Bakermans-Kranenburg and
van Ijzendoorn, 2014). We did not find any associations to other
clinical symptoms. This could partly be due to a low mean value
for the symptom measures in question.
Only a few case–control studies have investigated the relation-
ship between the diagnosis of schizophrenia and oxytocin-related
genes, using different strategies for SNP selection in the oxy-
tocin pathway genes and the results appear inconclusive (Souza
et al., 2010; Teltsh et al., 2011; Watanabe et al., 2012; Montag
et al., 2013). We did not find any associations between oxy-
tocin pathway genes, including in the form of PGRS for the
oxytocin pathway, and the diagnosis of a psychotic disorder.
This is in line with findings from the PGC schizophrenia sam-
ple where no SNPs in these four genes remained statistically
significant after Bonferroni gene-wide correction (published at
http://www.broadinstitute.org/mpg/ricopili/).
Due to overlapping symptomatology and susceptibility genes
across severe mental disorders (Levy and Manove, 2012; Crad-
dock and Sklar, 2013; Kidd, 2013) we here sought to include a
wide range of diagnoses and due to evidence of shared clinical
symptoms, genetic risk (Andreassen et al., 2013), neurocognitive
impairments (Simonsen et al., 2011) as well as brain abnormalities
(Rimol et al., 2010; Brandt et al., 2014) we also included patients
with BD. This could potentially weaken associations. A follow-
up analysis focusing only on patients with schizophrenia did not
however change the results.
While the current sample is large compared to previous samples
with structured information on clinical symptomatology, it is still
on the smaller side compared to the consortia based case–control
GWAS samples. We thus also run the risk of both type I and type
II errors, which is why we have chosen to present both nominal
and Bonferroni-corrected significance levels (Table 2), as a full
Bonferroni correction is based on the assumption of complete
independence between measures.
So to conclude: our findings suggest that oxytocin-related genes
are not main contributors to the risk of developing schizophrenia
or other psychotic disorders, but support the notion that specific
variation in the OXTR gene might play a role in the magnitude of
altered social behavior observed in patients with these disorders.
Theoretically, genetic or environmental risk factors can be associ-
ated with the risk for a particular disease phenotype in addition
to – or independent from – the risk for the disorderper se (Aas et al.,
2012; Varese et al., 2012; Pranavchand and Reddy, 2013). The effect
of medication is also often unrelated to the genetic underpinnings
of the disorder, and could explain why intra-nasally administered
oxytocin have a symptomatic effect in patients with schizophrenia
(Bujanow, 1972; Feifel et al., 2010; Pedersen et al., 2011; Fischer-
Shofty et al., 2013a; Lee et al., 2013; Modabbernia et al., 2013) even
if schizophrenia appears to not be related to oxytocin genetic vari-
ants. In light of a proposed interactionist model suggesting that
the treatment effect of oxytocin is dependent on personality traits
and context (Bartz et al., 2011; Luminet et al., 2011; Cardoso et al.,
2012; Strathearn et al., 2012), our finding suggests that the level of
negative symptoms, in particular Emotional Withdrawal, should
be of interest in further oxytocin trials in this patient group.
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